Term
|
Definition
LDL = Tc - (HDL + VLDL) where VLDL = TG/5 |
|
|
Term
Name 3 basic strategies to improve lipid profile |
|
Definition
1. Lower LDL 2. Lower plasma TG 3. Increased synth of ApoA-1 and ApoA-1 increases HDL conc |
|
|
Term
4 methods of lowering plasma LDL concentrations |
|
Definition
1. Increase hepatice LDL Receptors 2. Decrease the synthesis of ApoB100 to decrease the hep prod of VLDL 3. Increase the rate of clearance of VLDL and IDL cholesterol 4. decr plasma TG results in the production of larger less easily oxidized LDL particles. |
|
|
Term
2 strategies to lower plasma TG conc |
|
Definition
1. decrease the synth of ApoB100 decr prod for hep VLDL 2. activate peroxisom proliferator actvated Receptor alpha |
|
|
Term
What does PPAR alpha activation do? |
|
Definition
1. Increase the oxidation of fatty acids thus reduces the availabiltiy of substrate needed for synthesis of TGs 2. increases the synth of lipoprotein lipase an enzyme which increases the clearance fo TG rich lipoproteins 3. reduces the expr. of the hep gene coding for ApoC-3 b/c ApoC-3 inhibits the receptor mediated and lipolytic clearance of VLDL |
|
|
Term
Name the statins which are met by CYP3A4 |
|
Definition
Fluvastatin Atorvastatin Lovastatin Simvastatin |
|
|
Term
Name the statins with few D-D interactions |
|
Definition
Pravastatin Rosuvastatin have good PR |
|
|
Term
|
Definition
inhibit HMG-CoA reductase which inh the prod of cholesterol depleted sterol pool leads to increased synthesis of hepatic LDL receptors which increases clearance of LDL and IDL from plasma |
|
|
Term
overiding caveot of statins |
|
Definition
Both LDL-R and HMG-CoA production are induced by low cholesterol levels. thus the effects of statins are blunted |
|
|
Term
do statins work without LDL-receptors |
|
Definition
NO - only a 7-10 % fall is seen, you need the plasma reuptake of LDL- receptors to get the full effect. Just blocking chol synth with HMG-CoA inhib isn't enough. |
|
|
Term
Statin effect on VLDL metabolism |
|
Definition
|
|
Term
Statins that will decrease LDL 30 to 35% |
|
Definition
Lovastatin Atorvastatin Rosuvastatin Simvastatin |
|
|
Term
Other cardio protective effects of the statins |
|
Definition
1. Increased stability of cholesterol plaques 2. Reversal of endothelial dysfxn with improved ability to synthesize NO 3. decreased oxidation of LDL cholesterol 4. an antiinflammatory effects which produces a fall in the plasma concentration of CRP |
|
|
Term
|
Definition
Hepatic - so make a baseline AST ALT meas Myopathy - incr in plasma creatine phosphokinase with or w/o myalgia |
|
|
Term
|
Definition
Hepatic - so make a baseline AST ALT meas Myopathy - incr in plasma creatine phosphokinase with or w/o myalgia |
|
|
Term
|
Definition
clarithro, fluconazole, fluoxetine, fluvoxamine, metronidazole, nefazodone, sertraline, zafirlukast, verapamil, and amiodarone |
|
|
Term
Increased Myopathy with what drug combo? |
|
Definition
statin + gemfibrozil or niacin |
|
|
Term
Inh of CYP3A4 by other drugs increases the probability that which statin drugs will produce myalgia? |
|
Definition
Atovastatin Lovastatin Simvastatin |
|
|
Term
Inh of CYP2C9 will increase myalgia with |
|
Definition
|
|
Term
|
Definition
warfarin cimetidine, phenytoin, omeprazole, and amiodarone |
|
|
Term
|
Definition
release of massive myoglobin, occludes PT lumen - leads to ARF |
|
|
Term
|
Definition
|
|
Term
|
Definition
blocks the protein mediated transporter which absorbs dietary cholesterol from GI tract - leads to increased LDL-R and induction of HMG-CoA by sterol stat |
|
|
Term
Therapeutic uses of Ezetimibe |
|
Definition
used with a statin allows a large decrease in the daily statin dose without losing the beneficial effect of a statin |
|
|
Term
|
Definition
Liver toxicity does NOT increase risk of myopathy NO effect of CYPs so no D-D interactions Preg Cat C = Bad |
|
|
Term
|
Definition
cholestyramine colestipol colesevelan |
|
|
Term
|
Definition
swap Cl- for neg charged bile acids which decreases chol abs which decreases sterol pool which upregulates LDL-R and HMG-CoA |
|
|
Term
DO Resins work w/o LDL -R |
|
Definition
|
|
Term
Ion exchange resin toxicities |
|
Definition
GI - Const, bloating and pain Bind other drugs and prev abs - warfarin, propranolol, tetracyclines, furosemides, hydrochlorothiazides, pravastatin, fluvastatin, and thyroxine |
|
|
Term
If you have to take a resin which one do you take |
|
Definition
Colesevelan - Preg cat B and does not affect bioavail of digoxin, lovastatin, atorvastatin, simvastatin, and warfarin |
|
|
Term
|
Definition
It inhibits lipolysis in adipocytes which leads to decreased plasma FFA's and decreased plasma FFA's decreases hep synth of TG's -> decreased synth of hep TG reduces the synth of VLDL
activation of lipoprotein lipase increases the clearance of VLDL
BIG - decr in rate of catab of apoA-1 increases plasma HDL |
|
|
Term
Used to treat patients with low HDL and high TG? |
|
Definition
|
|
Term
|
Definition
Preg C flusing at first GI nausea and vom Gout |
|
|
Term
Big contraindication for Niacin |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
bind to PPAR alpha in liver, brown adipose, sk m., heart and kidnery to cause a decrease plasma TG via increased clearance of VLDL
gives increased peroxisomes, lipoprotein lipase, and reduces expression of ApoC-3 which inh clearance of VLDL stimulates Apoa-1 and apoa-3 leading to incr HDL incr hep rel of SREBP which increases LDL-R and HMG-CoA Red |
|
|
Term
Drugs which significantly increase HDL synth |
|
Definition
|
|
Term
|
Definition
|
|
Term
Drugs not safe for diabetics |
|
Definition
|
|
Term
only drugs somewhat safe for preg |
|
Definition
|
|
Term
only drugs somewhat safe for preg |
|
Definition
|
|
Term
Do you get myopathy with fibrates? |
|
Definition
Yes, but use fenofibrate as opposed to gem for a lower risk of myopathy |
|
|
Term
|
Definition
activates PPAR alpha to enhance FA oxid in liver and sk muscle which reduces the substrate available for VLDL
Direct activation of lipoprotein lipase enhances the clearance of TG rich VLDL
incr degr of apoB100
incr hep glycogen synth |
|
|